BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic

Reuters03-17

March 17 (Reuters) - HCW Biologics Inc HCWB.O:

HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC
HCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECH
HCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTS

Source text: ID:nGNXcc37Tx

Further company coverage: HCWB.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620421501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620421501","market":"nz","top_or_hot":-1,"title":"BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic</title></head><body><p><span>March 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/HCWB\">HCW Biologics</a> Inc <span>HCWB.O</span>:</p><ul><li><p>HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC</p></li><li><p>HCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECH</p></li><li><p>HCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTS</p></li></ul><p>Source text: <span>ID:nGNXcc37Tx</span></p><p>Further company coverage: <span>HCWB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 19:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic</title></head><body><p><span>March 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/HCWB\">HCW Biologics</a> Inc <span>HCWB.O</span>:</p><ul><li><p>HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTIC</p></li><li><p>HCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECH</p></li><li><p>HCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTS</p></li></ul><p>Source text: <span>ID:nGNXcc37Tx</span></p><p>Further company coverage: <span>HCWB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN4050JP:1","article_id":"2620421501","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620421501","pubTimestamp":1773748288,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion ImmunotherapeuticMarch 17 (Reuters) - HCW Biologics Inc HCWB.O:HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE L","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","HCWB":"HCW Biologics Inc."},"translate_title":"简介-Hcw Biologics关闭Hcw11-006（一种高潜力融合免疫治疗药物）的全球独家许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCWB":0.9},"content_text":"BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion ImmunotherapeuticMarch 17 (Reuters) - HCW Biologics Inc HCWB.O:HCW BIOLOGICS CLOSES EXCLUSIVE WORLDWIDE LICENSE FOR HCW11-006 – A HIGH POTENTIAL FUSION IMMUNOTHERAPEUTICHCW BIOLOGICS INC - RECEIVES $7.0 MILLION UPFRONT LICENSE FEE FROM BEIJING TRIMMUNE BIOTECHHCW BIOLOGICS INC - HAS FREE OPTION TO RECLAIM AMERICAS RIGHTSSource text: ID:nGNXcc37TxFurther company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620421501","isCrawlerRequest":true}